JP2004532877A5 - - Google Patents

Download PDF

Info

Publication number
JP2004532877A5
JP2004532877A5 JP2003500091A JP2003500091A JP2004532877A5 JP 2004532877 A5 JP2004532877 A5 JP 2004532877A5 JP 2003500091 A JP2003500091 A JP 2003500091A JP 2003500091 A JP2003500091 A JP 2003500091A JP 2004532877 A5 JP2004532877 A5 JP 2004532877A5
Authority
JP
Japan
Prior art keywords
disease
prevention
treatment
disorder
disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003500091A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004532877A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/SE2002/001031 external-priority patent/WO2002096912A1/en
Publication of JP2004532877A publication Critical patent/JP2004532877A/ja
Publication of JP2004532877A5 publication Critical patent/JP2004532877A5/ja
Pending legal-status Critical Current

Links

JP2003500091A 2001-06-01 2002-05-29 治療に有効なニコチン性アセチルコリン受容体に対する新規なリガンド Pending JP2004532877A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29520601P 2001-06-01 2001-06-01
PCT/SE2002/001031 WO2002096912A1 (en) 2001-06-01 2002-05-29 Novel ligand for nicotinic acetylcholine receptors useful in therapy

Publications (2)

Publication Number Publication Date
JP2004532877A JP2004532877A (ja) 2004-10-28
JP2004532877A5 true JP2004532877A5 (enExample) 2006-01-05

Family

ID=23136711

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003500091A Pending JP2004532877A (ja) 2001-06-01 2002-05-29 治療に有効なニコチン性アセチルコリン受容体に対する新規なリガンド

Country Status (18)

Country Link
EP (1) EP1397366B1 (enExample)
JP (1) JP2004532877A (enExample)
KR (1) KR20040003021A (enExample)
CN (1) CN1294136C (enExample)
AT (1) ATE353332T1 (enExample)
BR (1) BR0210075A (enExample)
CA (1) CA2455341A1 (enExample)
DE (1) DE60218032T2 (enExample)
DK (1) DK1397366T3 (enExample)
ES (1) ES2280538T3 (enExample)
IL (1) IL158735A0 (enExample)
MX (1) MXPA03010996A (enExample)
NO (1) NO20035333D0 (enExample)
NZ (1) NZ529426A (enExample)
PT (1) PT1397366E (enExample)
SI (1) SI1397366T1 (enExample)
WO (1) WO2002096912A1 (enExample)
ZA (1) ZA200308779B (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
BR0309345A (pt) * 2002-04-18 2005-02-15 Astrazeneca Ab Composto ou sais farmaceuticamente aceitáveis do mesmo, composição farmacêutica, uso de um composto, e, métodos de tratamento ou profilaxia de doenças ou condições humanas, de distúrbios psicóticos ou de distúrbios de dano intelectual, e de jetlag, interrupção do hábito de fumar, dependência de nicotina, ânsias, dor e colite ulcerativa
MXPA04010191A (es) * 2002-04-18 2005-02-03 Astrazeneca Ab Compuestos de furilo.
ES2348282T3 (es) 2002-04-18 2010-12-02 Astrazeneca Ab Compuestos de tienilo.
EP1678183A1 (en) * 2003-10-21 2006-07-12 AstraZeneca AB Spirofuropyridine aryl derivatives
TW200813067A (en) * 2006-05-17 2008-03-16 Astrazeneca Ab Nicotinic acetylcholine receptor ligands
SA08290475B1 (ar) 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
PL2307389T3 (pl) 2008-06-20 2013-05-31 Astrazeneca Ab Pochodne dibenzotiazepiny i ich zastosowanie
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
CN103221411B (zh) 2010-05-17 2016-05-11 富瑞姆制药公司 (R)-7-氯-N-(奎宁环-3-基)苯并[b]噻吩-2-甲酰胺盐酸盐单水合物的晶型
GB201111704D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Novel compounds
GB201111705D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Compounds and their use
JO3115B1 (ar) 2011-08-22 2017-09-20 Takeda Pharmaceuticals Co مركبات بيريدازينون واستخدامها كمثبطات daao
AU2013259871A1 (en) 2012-05-08 2014-11-20 Forum Pharmaceuticals Inc. Methods of maintaining, treating or improving cognitive function
GB201209587D0 (en) 2012-05-30 2012-07-11 Takeda Pharmaceutical Therapeutic compounds
WO2014122474A1 (en) 2013-02-07 2014-08-14 Takeda Pharmaceutical Company Limited Piperidin-1 -yl and azepin-1 -yl carboxylates as muscarinic m4 receptor agonists
US10208016B2 (en) 2013-06-21 2019-02-19 Takeda Pharmaceutical Company Limited 1-sulfonyl piperidine derivatives as modulators of prokineticin receptors
GB201314286D0 (en) 2013-08-08 2013-09-25 Takeda Pharmaceutical Therapeutic Compounds
GB201318222D0 (en) 2013-10-15 2013-11-27 Takeda Pharmaceutical Novel compounds
GB201320905D0 (en) 2013-11-27 2014-01-08 Takeda Pharmaceutical Therapeutic compounds
TW201613864A (en) 2014-02-20 2016-04-16 Takeda Pharmaceutical Novel compounds
GB201616839D0 (en) 2016-10-04 2016-11-16 Takeda Pharmaceutical Company Limited Therapeutic compounds
GB201619514D0 (en) 2016-11-18 2017-01-04 Takeda Pharmaceuticals Co Novel compounds
JP2021138648A (ja) 2020-03-04 2021-09-16 武田薬品工業株式会社 経口固形製剤

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1110499C (zh) * 1997-05-30 2003-06-04 神经研究公司 螺一奎宁环衍生物,它们的制备和用途
AR013184A1 (es) * 1997-07-18 2000-12-13 Astrazeneca Ab Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis
SE9900100D0 (sv) * 1999-01-15 1999-01-15 Astra Ab New compounds

Similar Documents

Publication Publication Date Title
JP2004532877A5 (enExample)
EP4279070B1 (en) Composition comprising a benzoate salt of 5-methoxy-n,n-dimethyltryptamine
JP2003512374A5 (enExample)
JP2003514818A5 (enExample)
JP2003513073A5 (enExample)
PH12019500004A1 (en) 5,7-dihydro-pyrrolo-pyridine derivatives for treating neurological and neurodegenerative diseases
JP2006507241A5 (enExample)
JP2003513071A5 (enExample)
JP2005527588A5 (enExample)
JP2020514318A5 (enExample)
TWI657078B (zh) 作爲單胺氧化酶(mao)抑制劑之經取代之萘啶及喹啉化合物
ATE507207T1 (de) Kondensierte pyridazinderivat-verbindungen und die verbindungen als wirkstoff enthaltende arzneimittel
Mazurov et al. 2-(Arylmethyl)-3-substituted quinuclidines as selective α7 nicotinic receptor ligands
JP2007532637A5 (enExample)
ES2560095T3 (es) Amidas bicíclicas para mejorar las respuestas sinápticas glutamatérgicas
HRP20110524T1 (hr) Spojevi dihidropiridina za neurodegenerativne bolesti i demenciju
JP2001510194A5 (enExample)
JP2005534624A5 (enExample)
JP2005500357A5 (enExample)
JP2009537517A5 (enExample)
AU2022413759A1 (en) Benzoate salt of 5-methoxy-n,n-dimethyltryptamine
TW200829241A (en) Treatment of parkinson's disease
JP2019512469A5 (enExample)
JP2019534327A5 (enExample)
CA3102762A1 (en) Eaat2 activators and methods of using thereof